the canadian cancer society (ccs) is issuing a special call for grant applications focused on rare and aggressive uterine cancers, with an emphasis on uterine carcinosarcoma in particular. as a result of a generous donation, there is funding available to support one meritorious application that will impact our understanding of uterine carcinosarcoma and other aggressive uterine cancers, particularly as it relates to the prevention, early detection, diagnosis, and/or treatment of these hard-to-treat cancers. 

eligible types of uterine cancer include:

•   uterine carcinosarcoma
•   serous carcinoma
•   uterine leiomyosarcoma
•   uterine clear cell carcinoma
•   endometrial stromal sarcoma (high-grade)
•   undifferentiated sarcomas

 enable scientists in cardiovascular research from different countries to come together and build effective collaborations on a common interdisciplinary research project based on complementarities and sharing of expertise with a clear translation research approach for future clinical impact.

call for applications information and application form to apply to the law foundation of ontario’s responsive grants program
deadlines: small & major grant – march 31; small grant – september 1 (every year)
grant amounts: small grant – up to $15k; major grant – up to $100,000 and $100k to $250k

the fy20 defense appropriations act providing funding to the department of defense alsrp to support innovative and impactful research to develop new treatments for als.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

fy20 alsrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.    

https://cdmrp.army.mil/funding/alsrp

therapeutic development award - pre-application april 15, 2020

independent investigators at all academic levels (or equivalent)

• pre-application is required; full application submission is by invitation only.
• supports preclinical secondary validation and ind-enabling studies of therapeutics for als.
• preliminary data is required, including efficacy in at least one als-relevant model system with a lead molecule/class of compounds.
• biomarker development and/or characterization (if not already validated), in parallel to the main therapeutic effort, is a critical component of the tda proposal.
• maximum funding of $1,000,000 for direct costs plus indirect costs
• maximum period of performance is 3 years

therapeutic idea award - pre-application april 15, 2020

independent investigators at all academic levels (or equivalent)

• pre-application is required; full application submission is by invitation only.
• supports hypothesis-driven preclinical therapeutic development.
• preliminary data are not required.
• projects focusing primarily on investigating als pathophysiology are outside the scope of this award mechanism.
• early career investigators are encouraged to apply.
• therapeutic relevant biomarker option: applications which include the development of biomarkers in parallel with the main therapeutic advancement effort, and that meet the criteria outlined in the funding opportunity announcement, will qualify for a higher level of funding.
• maximum funding of $500,000 for direct costs plus indirect costs
• maximum funding of $600,000 for direct costs plus indirect costs if applying for the therapeutic relevant biomarker option
• maximum period of performance is 2 years

new for fy20! clinical development award - pre-application april 15, 2020

independent investigators at all academic levels (or equivalent) 

• pre-application is required; full application submission is by invitation only.
• supports leveraging of human-based als resources through correlative clinical research.
• early career investigators and/or early career physician scientists are encouraged to apply.
• types of efforts that will be supported include:

o  using human subject-based resources to better define subtypes, predict therapeutic response, or assess prognosis

o  correlating clinical trial-related biosamples, imaging, or epidemiological data with clinical outcomes

o  adding a secondary aim/goal to an anticipated/ongoing clinical trial, not otherwise supported by the trial

o  studies to evaluate optimizing components of current als clinical care

• maximum funding of $300,000 for direct costs plus indirect costs
• maximum period of performance is 2 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420.  

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the alsrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk 
301-682-5507 
help@ebrap.org

the namesake grant program was developed in 2016 to interconnect communities within canada and is administered by the canadian foundation for women's health (cfwh). these grants allow for local businesses and interested persons to offer support to meaningful research topics within women’s health.

the namesake grant program was developed in 2016 to interconnect communities within canada and is administered by the canadian foundation for women's health (cfwh). these grants allow for local businesses and interested persons to offer support to meaningful research topics within women’s health.

the dawn walker grant is administered by the canadian foundation for women's health (cfwh) in support of health policy training and development for healthcare professionals. for purposes of the grant, healthcare professionals are defined as individuals or 世界杯2022赛程表淘汰赛 working or learning in a healthcare field and whose success will benefit from an enhanced understanding of the development of better health program policy for children and women.

the canadian foundation for women’s health attributes up to two duchesnay fellowships every year to resident 世界杯2022赛程表淘汰赛 in obstetrics and gynaecology who desire to complete an elective in a health care center of a developing country. the fellowships cover four to eight weeks and the amount varies from $2,500cad to $4,500cad according to the length of the elective. a $700cad lump‐sum will be allocated to the local supervisor of the elective.

the cfwh general research grants are awarded to those committed to finding solutions to the reproductive health issues that face women both in canada and around the world. open to any area within the field of obstetrics and gynaecology, these grants aim to help make further advancements in women’s health treatment, research, and education. the cfwh general research grant has a value of up to $20,000.